ClinicalTrials.gg
CompletedNCT00202696Updated May 19, 2008

Nalmefene Smoking Cessation Study

A Phase 2 interventional study of nalmefene and Placebo in Smoking Cessation, sponsored by Somaxon Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2008-05-19.

Sponsored by Somaxon Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 920 studies in Smoking Cessation with a site in United States — 98 open to participants now, 126 under way, 7 of them phase 3. Smoking Cessation · United States.

Enrollment
557th of 872
76 · median 149
Started
2005
with 29 others
Phase 2
105 of 920
9 open now
Registered
36th of 920
by date

Among the 920 studies in Smoking Cessation with a site in United States, this one is the 557th largest by enrollment of the 872 interventional ones that give a count, is one of 30 that started in 2005, is one of 105 in phase 2, and was the 36th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

98 of the 920 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 920 studies in Smoking Cessation with a site in United States, or all of them as a file.
02

Study summary

To determine if nalmefene is safe and effective in smoking cessation.

Read the detailed description

Single centered, randomized, placebo-controlled,double-blind, outpatient pilot study to evaluate the efficacy, safety and tolerability of 2 doses of nalmefene on smoking cessation.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Smokers in good general health self reporting more than 15 cigarettes per day

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    1

    Nalmefene 40 mg

    Drug: nalmefene

  • Experimental
    2

    Nalmefene 80 mg

    Drug: nalmefene

  • Other
    3

    Placebo

    Other: Placebo

Interventions

  • Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).

  • OtherPlacebo

    Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).

06

What researchers measure

Primary outcomes

  1. Assess the efficacy of 2 doses of nalmefene relative to placebo

Secondary outcomes

  1. Evaluate the safety and tolerability of 2 doses of nalmefene

07

Study locations

1 site
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 20, 2005
Start
Sep 2005
Primary completionActual
Mar 2006
CompletionActual
Mar 2006
Last update
May 19, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00202696
Lead sponsor
Somaxon Pharmaceuticals
First posted
Sep 20, 2005
Start date
Sep 2005
Primary completion
Mar 2006
Completion
Mar 2006
Last update
May 19, 2008

Study contacts

Philip Jochelson, MD
study director · Somaxon Pharmaceuticals CMO

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion